Human Papilloma Virus-mediated Carcinoma of Cervix

Authors

  • Mullai Chelvi Munusamy
  • Durgadas N. Management and Science University,

DOI:

https://doi.org/10.37591/rrjoi.v3i2.1177

Abstract

Cervical cancer is a major global health problem, with more than 500,000 new cases being reported each year and an estimated 275,000 women dying from it annually. One of the important causes of this cancer is human papilloma virus (HPV). Of the several types of HPV, type 16 and 18 are considered to be the main types that mediate the development of cervix carcinoma. The high-risk types cause not only cervix carcinoma, but also cause significant number of penile, vaginal, anal and oropharyngeal cancer. Two effective prophylactic vaccines are available to prevent this cancer. The opportunities to prevent HPV-mediated carcinoma of cervix include the availability of safe and effective vaccines and diagnostic tests; screening Pap smear test and molecular tests. The availability of molecular technique not only brings specificity to tests but also helps in identifying HPV genotype. This could help in epidemiology of HPV type distribution in a given region. The main challenges are the high cost of vaccine, health education, cultural and religious issues, and proper counseling. Proper planning is required to provide health education to general population and proper training in counseling to the health workers. The strategy should also consider the other types that are of oncogenic potential and oropharyngeal cancer caused by these genotypes.

 

Keywords: Human papilloma virus, genotypes, cervical cancer, vaccination, prevention 

Downloads

Published

2019-04-02

Issue

Vol. 3 No. 2 (2013)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.